Skip Navigation


Annals of Oncology Advance Access originally published online on June 20, 2008
Annals of Oncology 2008 19(11):1847-1852; doi:10.1093/annonc/mdn395
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/11/1847    most recent
mdn395v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sirohi, B.
Right arrow Articles by Smith, I. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sirohi, B.
Right arrow Articles by Smith, I. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

breast cancer

Platinum-based chemotherapy in triple-negative breast cancer

B. Sirohi{dagger}, M. Arnedos, S. Popat, S. Ashley, A. Nerurkar, G. Walsh, S. Johnston and I. E. Smith*

Breast Unit, Royal Marsden NHS Foundation Trust, London

* Correspondence to: Prof. I. E. Smith, Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK. Tel: +44-20-7808-2751; Fax: +44-20-7352-5441; E-mail: ian.smith{at}rmh.nhs.uk

Background: Experimental data suggest that triple-negative (TN) breast cancer may have increased sensitivity to platinum-based chemotherapy but clinical data are limited. We present our long-term results with platinum-based chemotherapy for TN breast cancer.

Patients and methods: In all, 94 (17 TN), 79 (11 TN) and 155 (34 TN) patients receiving platinum-based chemotherapy in neo-adjuvant/adjuvant and advanced setting were included. Response rates and outcome were compared for TN tumours versus others.

Results: Neo-adjuvant complete response rates were significantly higher for TN tumours (88%) than others (51%; P = 0.005). The 5-year overall survival (OS) for TN tumours following adjuvant/neo-adjuvant chemotherapy was 64% [95% confidence interval (CI) 44% to 79%] compared with 85% (95% CI 79% to 90%) for others. Five-year disease-free survival for TN tumours was 57% (95% CI 37% to 73%) compared with 72% (95% CI 64% to 78%) for others. For patients with advanced breast cancer, overall response rates were 41% for TN tumours and 31% for others (P = 0.3). Patients with TN tumours had a significantly prolonged progression-free survival of 6 months compared with 4 months for others (P = 0.05), though the OS was not significantly different between the two groups (11 versus 7 months).

Conclusion: Platinum-based chemotherapy achieves increased response rates for TN tumours, with a trend towards worse survival in early breast cancer through an improved survival in advanced disease. Prospective randomised trials are warranted.

Key words: breast cancer, early and advanced, platinum chemotherapy, triple-negative

{dagger} Current address: Oncology Centre, Addenbrookes Hospital, Hills Road, Cambridge CB2 2QQ, UK

Received for publication January 8, 2008. Accepted for publication May 21, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
O. Gluz, C. Liedtke, N. Gottschalk, L. Pusztai, U. Nitz, and N. Harbeck
Triple-negative breast cancer--current status and future directions
Ann. Onc., December 1, 2009; 20(12): 1913 - 1927.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Frasci, G. D'Aiuto, P. Comella, M. D'Aiuto, M. Di Bonito, P. Ruffolo, G. Iodice, A. Petrillo, S. Lastoria, P. Oliviero, et al.
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908
Ann. Onc., October 8, 2009; (2009) mdp356v1.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
V. Guarneri and P. Conte
Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy
Oncologist, July 1, 2009; 14(7): 645 - 656.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.